Anti-Human CD257 (BAFF) (Tabalumab)
Catalogue Number: 12-8030-ABO
| Manufacturer: | Abeomics |
| Type: | Recombinant Monoclonal |
| Alias: | DTL; BLYS; TALL1; THANK; ZTNF4; TALL-1; TNLG7A; TNFSF20; TNFSF13B |
| Shipping Condition: | Blue Ice |
| Unit(s): | 100 ug, 50 ug |
| Host name: | Human |
| Clone: | Tabalumab |
| Isotype: | IgG1, kappa |
| Immunogen: | Original antibody was raised against soluble human BAFF. |
| Application: | ELISA |
Description
Description: Expression Host : HEK-293 Pathogen Testing : To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of this recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile. This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Tabalumab. Tabalumab neutralizes soluble human, cynomolgus monkey, and rabbit BAFF. Additionally, Tabalumab neutralizes membrane-bound BAFF. This product is for research use only. Tabalumab is a human monoclonal anti-B-cell activating factor (BAFF) antibody intended for the treatment of autoimmune diseases and B cell malignancies.1 BAFF is a membrane-bound, type II transmembrane protein that belongs to the tumor necrosis factor (TNF) ligand family and is the ligand for BR3, TACI, and BCMA. BAFF is an immunostimulant necessary for maintaining normal immunity. This cytokine has also been shown to play an important role in the proliferation and differentiation of B cells. An inadequate level of BAFF leads to immunodeficiency whilst an elevated level of BAFF causes unusually high antibody production that results in the development of autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. Additionally, BAFF has been found in renal transplant biopsies with acute rejection.2 Furthermore, BAFF may be a mediator of food-related inflammation, and is associated with multiple dietary ailments including celiac disease, insulin resistance, diabetes, and obesity.3 Interestingly, it is suspected that BAFF may be involved in non-IgE-mediated reactions because there is no known correlation between BAFF and IgE.4 More research is needed to unlock the enormous therapeutic potential for BAFF antagonists. This cost-effective, research-grade Anti-Human CD257 (BAFF) (Tabalumab) utilizes the same variable regions from the therapeutic antibody Tabalumab making it ideal for research projects.
Additional Text
Antibody Clonality
Monoclonal
Application Notes
Endotoxin : <= 1.0 EU/mg as determined by the LAL method The suggested concentration for Tabalumab biosimilar antibody for staining cells in flow cytometry is <= 0.25 µg per 106 cells in a volume of 100 µl. Titration of the reagent is recommended for optimal performance for each application.
12-8030 Datasheet
SUPPORT
outstanding technical support
PRODUCT
we offer a full product guarantee
DELIVERY
we offer free delivery to UK universities and non profit organisations